Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524804 | NSE Symbol : AUROPHARMA | ISIN : INE406A01037 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
17-Jan-2025	06-Feb-2025	Quarterly Results	AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2025 inter alia to consider and approve Intimation of Board Meeting to be held on February 6 2025 to consider and approve inter alia the standalone and consolidated Unaudited financials results of the company for the third quarter and Nine months period ended December 312024 Intimation of outcome of the Board meeting held on February 6, 2025 (As Per Bse Announcement Dated on 06.02.2025)
01-Nov-2024	09-Nov-2024	Quarterly Results	AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2024 inter alia to consider and approve Intimation of Board meeting to be held on Saturday November 9 2024 to consider and approve inter alia the Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2024. In accordance with the provisions of Regulations 30 and all other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company at its meeting held today, November 9, 2024, has inter alia, considered and approved the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2024, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. (As Per BSE Announcement Dated on 09.11.2024) Submitting the corrigendum to the unaudited financial results for the quarter and half year ended 30.09.2024. (As Per BSE Announcement Dated on 10.11.2024) In accordance with the provisions of Regulations 30 and all other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company at its meeting held today, November 9, 2024, has inter alia, considered and approved the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2024, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. (As Per BSE Announcement Dated on: 09/11/2024)
31-Jul-2024	10-Aug-2024	Quarterly Results	AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2024 inter alia to consider and approve Intimation of Board Meeting to be held on August 10 2024 to consider and approve interalia the financial results for the first quarter ended June 30 2024. Submission of outcome of Board meeting (As Per BSE Announcement Dated on: 10/08/2024)
14-Jul-2024	18-Jul-2024	Buy Back	AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/07/2024 inter alia to consider and approve A meeting of the Board of Directors of the Company will be held on Thursday July 18 2024 to consider inter alia a proposal for buyback of the fully paid-up equity shares of the Company and the matters necessary and incidental thereto in accordance with the applicable provisions under the Companies Act 2013 the Securities and Exchange Board of India (Buy-back of Securities) Regulations 2018 and other applicable laws Intimation of outcome of Board meeting where the Board has approved buyback of equity shares of the Company. (As per BSE Announcement Dated on 18/07/2024)
16-May-2024	25-May-2024	Accounts	AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2024 inter alia to consider and approve Consideration and approval of inter alia audited financial results for the 4th quarter and the financial year ended on March 31 2024. Submission of outcome of Board meeting held on 25th May 2024 Submission of Audited Financial Results for the fourth quarter and financial year ended on March 31, 2024 Intimation of reappointment / continuation of directors subject to approval of shareholders (As Per BSE Announcement Dated on 25/05/2024)
27-Mar-2024	27-Mar-2024	Change in Directors	Intimation of changes in Board of Directors of the Company
01-Feb-2024	10-Feb-2024	Quarterly Results	AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 inter alia to consider and approve Intimation of Board meeting on Saturday 10th February 2024 for consideration of unaudited standalone and consolidated financial results for the 3rd quarter and 9 month period ended on 31st December 2023. The Board of Directors in its meeting convened to be held on 10th February 2024 will also consider the payment of second interim dividend, if any, for the financial year 2023-24. (As Per BSE Announcement dated on 07.02.2024) Board of Directors in their meeting held today, February 10, 2024, approved the payment of Second Dividend of 150% i.e. Rs.1.50 per shares of Re.1 each. Board of Directors in their meeting held today, February 10, 2024, appointed Dr. Deepali Pant Joshi as an Independent Director (subject to approval of shareholders) and accepted the resignation of Dr. Avnit Bimal Singh as an Independent Director. (As Per BSE Announcement Dated on 10.02.2024)
27-Oct-2023	09-Nov-2023	Interim Dividend	AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform that a Meeting of the Board of Directors of the Company will be held on Thursday November 9 2023 to consider and approve inter alia the following: 1. Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2023 and 2. payment of Interim Dividend if any for the financial year 2023-24. Intimation of November 20, 2023 as Record Date for payment of Interim Dividend for FY 2023-24, if declared. (As Per BSE Announcement Dated on 02.11.2023) The Board of Directors of the Company at its meeting held today, November 9, 2023, has inter alia, transacted the following items of business: 1. Approved the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. 2. Approved first interim dividend of 300% i.e., Rs.3.00 (Rupees three only) per equity share of Re.1/- each on the equity share capital of the Company. The Company has already fixed November 20, 2023 as the record date for the purpose of payment of interim dividend for the financial year 2023-24 and the said interim dividend will be paid on or before December 4, 2023. 3. Based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the members through postal ballot, approved the appointment of Dr.Satakarni Makkapati (DIN. 09377266) as Nonexecutive and Non-independent Director of the Company with effect from November 9, 2023. 4. Approved purchase of entire equity shares of Theranym Biologics Private Limited, a step-down wholly owned subsidiary of the Company, from Curateq Biologics Private Limited, also a wholly owned subsidiary of the Company and make Theranym Biologics Private Limited a direct subsidiary of the Company. The Board meeting commenced at 3.30 p.m. and concluded at 7.00 p.m. Outcome of Board meeting held on 9th November 2023 Board has approved the acquisition entire equity share capital of Theranym Biologics Private Limited, a 100% stepdown subsidiary, to make it a direct subsidiary. Board of Directors appointed Dr. Satakarni Makkapati as Non-executive and Non-independent Director of the Company. (As Per BSE Announcement Dated on 09.11.2023)
03-Aug-2023	12-Aug-2023	Quarterly Results	AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2023 inter alia to consider and approve We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 that a Meeting of the Board of Directors of the Company will be held on Saturday August 12 2023 to consider and approve inter alia the Standalone & Consolidated Unaudited Financial Results of the Company for the first quarter ended June 30 2023. Further to our letter dated June 28 2023 informing the closure of Trading Window of the Company from July 1 2023 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the first quarter ended June 30 2023 we inform you that the Trading Window will remain closed up to August 14 2023 and shall be re-opened on August 15 2023. The Board of Directors of the Company at its meeting held today, August 12, 2023, has inter alia, considered and approved the standalone and consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2023, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors of the Company. The Board meeting commenced at 3.30 p.m. and concluded at 5.40 p.m. Board has approved the following in its meeting held today, 12 August 2023: Has reinitiated to explore restructuring of Eugia Pharma Specialities Limited and Has accepted the resignation of Dr.M.Sivakumaran as Whole-time Director and Director of the Company w.e.f. August 24, 2023 The Board of Directors in its meeting held today, August 12, 2023, has accepted the resignation of Dr. M. Sivakumaran as Whole-time Director and Director of the Company on close of business hours of August 24, 2023. (As per BSE Announcement Dated on 12/08/2023)
18-May-2023	27-May-2023	Accounts	AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2023 inter alia to consider and approve We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 that a Meeting of the Board of Directors of the Company will be held on Saturday May 27 2023 to consider and approve inter alia the Standalone & Consolidated Audited Financial Results of the Company for the fourth quarter and year ended March 31 2023. The Board of Directors of the Company at its meeting held today, May 27, 2023, has inter alia, considered and approved the standalone and consolidated Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2023, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Audited Financial Results of the Company along with the Audit Reports issued by the Statutory Auditors of the Company. Pursuant to Regulation 33(3)(d) of SEBI Listing Regulations, we hereby confirm and declare that the Statutory Auditors of the Company, M/s. Deloitte Haskins & Sells, Chartered Accountants, have issued the audit reports on Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2023, with unmodified opinion. (As Per BSE Announcement Dated on 27.05.2023)
01-Apr-2023	01-Apr-2023	Others	The Board of Directors of Aurobindo Pharma Limited ('the Company') at its meeting held today i.e. April 01, 2023 has approved the following business transactions a. Transfer of units constituting Antibiotic API Division of the Company to Apitoria Pharma Private Limited (formerly known as Auro Pharma India Private Limited), a wholly owned subsidiary of the Company by way of slump sale through a Business Transfer Agreement(s). We refer to our letter dated August 12, 2021 informing about the approval of the Scheme of Amalgamation by the Board of Director of the Company, providing for the amalgamation of wholly owned subsidiaries of the Company viz., Auronext Pharma Private and Mviyes Pharma Ventures Private Limited with the Company subject to the requisite statutory I regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench). (As Per BSE Announcement Dated on 01/04/2023)
31-Jan-2023	09-Feb-2023	Quarterly Results	AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform that a Meeting of the Board of Directors of the Company will be held on Thursday February 9 2023 to consider and approve inter alia the following: 1. Standalone & Consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31 2022 and 2. Payment of Interim Dividend if any for the financial year 2022-23. Further to our letter dated December 29 2022 informing about the closure of Trading Window of the Company from January 1 2023 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31 2022 we inform you that the Trading Window will remain closed up to February 11 2023 and shall be re-opened on February 12 2023. The Board of Directors of the Company at its meeting held today, February 9, 2023, has inter alia, transacted the following items of business: 1. Approved the standalone and consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2022, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors. 2. Approved first interim dividend of 300% i.e. Rs.3.00 (Rupees three only) per equity share of Re.1/- each on the equity share capital of the Company. The Company has already fixed February 17, 2023 as the record date for the purpose of payment of interim dividend for the financial year 2022-23. The interim dividend will be paid on or before March 3, 2023. The Board of Directors of the Company at its meeting held today, February 9, 2023, has inter alia approved amendments in Articles of Association of the Company, subject to the approval of members of the Company through postal ballot. (As Per BSE Announcement Dated on 09.02.2023)
14-Dec-2022	14-Dec-2022	Change in Directors	We hereby inform that based on the recommendation of Nomination, Remuneration and Compensation Committee and subject to the approval of the members of the Company by way of special resolution through Postal Ballot, the Board of Directors of the Company approved today, 14th December 2022, the reappointment of Mr. Girish Paman Vanvari (DIN: 07376482) as an Independent Director of the Company for the second term of 5 (five) consecutive years w.e.f. 5th November 2022. Necessary details as prescribed in SEBI Circular dated 9th September 2015 are provided in Annexure.
31-Oct-2022	12-Nov-2022	Quarterly Results	AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2022 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform that a Meeting of the Board of Directors of the Company will be held on Saturday November 12 2022 to consider and approve inter alia the Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2022. Further to our letter dated September 28 2022 informing the closure of Trading Window of the Company from October 1 2022 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2022 we inform you that the Trading Window will remain closed up to November 14 2022 and shall be re-opened on November 15 2022. Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing copies of newspaper advertisement of the financial results of the company for the second quarter and half year ended September 30, 2022, as published in Business Standard and Nava Telagana on November 14, 2022. (As Per BSE Announcement Dated on 14.11.2022) Further to our letters dated, November 10 & 11, 2022, the Board of Directors of the Company in its meeting held today, November 12, 2022, decided the following: In view of temporary inability to perform executive functions of the Company by Mr.P. Sarath Chandra Reddy, he has been relieved from his executive responsibilities he was performing. However, he will continue to remain as director on the Board of the Company. (As Per BSE Announcement Dated 12.11.2022)
03-Aug-2022	11-Aug-2022	Quarterly Results	AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2022 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform that a Meeting of the Board of Directors of the Company will be held on Thursday August 11 2022 to consider and approve inter alia the Standalone & Consolidated Unaudited Financial Results of the Company for the first quarter ended June 30 2022. Further to our letter dated June 28 2022 informing the closure of Trading Window of the Company from July 1 2022 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the first quarter ended June 30 2022 we inform you that the Trading Window will remain closed up to August 13 2022 and shall be re-opened on August 14 2022. The Board of Directors of the Company at its meeting held today, August 11, 2022, has, inter alia, considered and approved the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2022 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company. We also enclose a copy of the Press Release on the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2022. (As Per BSE Announcement Dated 11.08.2022)

1 2

LOGIN HERE

Aurobindo Pharma Ltd

Board Meeting